Foghorn Therapeutics is developing precision therapeutics that remodel DNA structure to correct abnormal gene expression linked to over half of all cancers and various other diseases. By targeting the chromatin regulatory system, these therapies aim to restore normal gene function and improve treatment outcomes in oncology and beyond.
Funding
$110M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and other diseases are linked to malfunctions within the chromatin regulatory system, which controls gene expression by managing the 3D structure of DNA. When this system breaks down, it leads to abnormal gene expression, causing cells to turn genes on or off at inappropriate times.
Solution
Foghorn Therapeutics is developing precision therapeutics designed to remodel DNA structure and correct abnormal gene expression associated with diseases. By targeting dependencies within the chromatin regulatory system, their therapies aim to restore normal gene function. These therapeutic candidates change how genes are turned on and off, offering a potential new approach to treating cancer and other diseases.
Target Audience
The primary target audience includes patients suffering from cancers and other diseases linked to malfunctions in the chromatin regulatory system.
Features
- Therapeutic candidates that remodel the 3D structure of DNA.
- Precision targeting of the chromatin regulatory system to correct abnormal gene expression.
- Focus on restoring normal gene function in affected cells.
- Potential application in oncology and other disease areas beyond cancer.